Kokame Koichi, Matsumoto Masanori, Soejima Kenji, Yagi Hideo, Ishizashi Hiromichi, Funato Masahisa, Tamai Hiroshi, Konno Mutsuko, Kamide Kei, Kawano Yuhei, Miyata Toshiyuki, Fujimura Yoshihiro
Research Institute, National Cardiovascular Center, Suita, Osaka 565-8565, Japan.
Proc Natl Acad Sci U S A. 2002 Sep 3;99(18):11902-7. doi: 10.1073/pnas.172277399. Epub 2002 Aug 14.
von Willebrand factor (VWF) is synthesized primarily in vascular endothelial cells and secreted into the plasma as unusually large VWF multimers. Normally, these multimers are quickly degraded into smaller forms by a plasma metalloproteinase, VWF-cleaving protease (VWF-CP). Decreases in the activity of this enzyme result in congenital and acquired thrombotic thrombocytopenic purpura (TTP). The human VWF-CP has recently been purified. Cloning of the corresponding cDNA revealed that the 1,427-aa polypeptide is a member of the ADAMTS gene family, termed ADAMTS13. Twelve rare mutations in this gene have been identified in patients with congenital TTP. Here, we report missense and nonsense mutations in two Japanese families with Upshaw-Schulman syndrome, congenital TTP with neonatal onset and frequent relapses. The comparison of individual ADAMTS13 genotypes and plasma VWF-CP activities indicated that the R268P, Q449stop, and C508Y mutations abrogated activity of the enzyme, whereas the P475S mutant retained low but significant activity. The effects of these mutations were further confirmed by expression analysis in HeLa cells. Recombinant VWF-CP containing either the R268P or C508Y mutations was not secreted from cells. In contrast, Q449stop and P475S mutants were normally secreted but demonstrated minimal activity. Genotype analysis of 364 Japanese subjects revealed that P475S is heterozygous in 9.6% of individuals, suggesting that approximately 10% of the Japanese population possesses reduced VWF-CP activity. We report on a single-nucleotide polymorphism associated with alterations in VWF-CP activity; it will be important to assess this single-nucleotide polymorphism as a risk factor for thrombotic disorders.
血管性血友病因子(VWF)主要在血管内皮细胞中合成,并以异常大的VWF多聚体形式分泌到血浆中。正常情况下,这些多聚体很快被血浆金属蛋白酶——VWF裂解蛋白酶(VWF-CP)降解为较小的形式。该酶活性降低会导致先天性和获得性血栓性血小板减少性紫癜(TTP)。人类VWF-CP最近已被纯化。相应cDNA的克隆显示,1427个氨基酸的多肽是ADAMTS基因家族的成员,称为ADAMTS13。在先天性TTP患者中已鉴定出该基因的12种罕见突变。在此,我们报告了两个患有Upshaw-Schulman综合征(先天性TTP,新生儿期发病且频繁复发)的日本家族中的错义突变和无义突变。个体ADAMTS13基因型与血浆VWF-CP活性的比较表明,R268P、Q449stop和C508Y突变消除了该酶的活性,而P475S突变体保留了低但显著的活性。这些突变的影响通过在HeLa细胞中的表达分析得到进一步证实。含有R268P或C508Y突变的重组VWF-CP未从细胞中分泌出来。相比之下,Q449stop和P475S突变体正常分泌,但活性极低。对364名日本受试者的基因型分析显示,9.6% 的个体中P475S是杂合子,这表明约10% 的日本人群具有降低的VWF-CP活性。我们报告了一个与VWF-CP活性改变相关的单核苷酸多态性;将该单核苷酸多态性评估为血栓性疾病的危险因素很重要。